Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01699737 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Akros Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 325
- Enrollment target
NCT01699737: Completed Phase 2 study, sponsored by Akros Pharma.
NCT01699737 is a Phase 2 study that has completed, run by Akros Pharma. The registered enrollment target is 325 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (144% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01699737, a Phase 2 study, has completed, sponsored by Akros Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 325 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of JTT-851 on diabetes as well as to assess the safety, tolerability, and pharmacokinetics of JTT-851 in type 2 diabetic patients either treated with metformin or treatment-naïve.
Primary Outcome
To investigate the change in glycosylated hemoglobin (HbA1c) after JTT-851 administration, once daily for 12 weeks
Interventions
- DRUG Glimepiride
- DRUG JTT-851
- DRUG Placebo for Active
- DRUG Placebo for comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
What the finished NCT01699737 record still lists
NCT01699737 is an interventional study that assigns participants to a tested intervention. The registered 325 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (144% higher).
The record links to 0 conditions, and to 4 interventions - of which Glimepiride is the first listed.
NCT01699737 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01699737 about?
NCT01699737 is a clinical study titled "Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the effect of JTT-851 on diabetes as well as to assess the safety, tolerability, and pharmacokinetics of JTT-851 in type 2 diabetic patients either treated with metformin or treatment-naïve.
What is the current status of trial NCT01699737?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 325 participants. The study started on 2012-09. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01699737?
The interventions under investigation include: Glimepiride (DRUG), JTT-851 (DRUG), Placebo for Active (DRUG), Placebo for comparator (DRUG).
Who is sponsoring clinical trial NCT01699737?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01699737's enrollment target sits among peer trials
325 148th of 2000 higher than 1,852 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02543983 · 325 participants · Phase 2
Neurobiology of Suicide
- NCT03016819 · 325 participants · Phase 3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- NCT03288207 · 325 participants · NA
Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments
- NCT04986657 · 325 participants · NA
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia